With this news, everyone is alerted that the game is fixed and the SEC is, so far, asleep at the wheel. Small investors are left to pick up their marbles (if they haven't already been stolen) or invest in a company like JNJ where inside information doesn't move the needle very much.
One thing about sorafenib is that it will be pretty difficult to demonstrate a survival benefit in its Phase 3. The DSMB halted the trial in March after the progression benefit was shown to be stat sig, and the placebo patients were granted access to the drug. Either way, there is not much doubt about sorafenib getting approved next quarter.
Market Data 
Markets 
AI
